A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

Molecular and Cellular Biology

Volumn 16, Issue 10, 1996, Pages 5276-5287

  Tzahar, Eldad ^a   Waterman, Hadassa ^a   Chen, Xiomei ^a   Levkowitz, Gil ^a   Karunagaran, Devarajan ^a,c   Lavi, Sara ^a   Ratzkin, Barry J ^b   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALIA;

EID: 0029814271     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.10.5276     Document Type: Article

References (62)

1. Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation and human mammary carcinoma cells. Oncogene 10:1813-1821.
2. Bargmann, C. I., and R. A. Weinberg. 1988. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA 85:5394-5398.
3. Beerli, R. R., W. Wels, and N. E. Hynes. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269: 23931-23936.
4. Ben-Levy, R., E. Peles, R. Goldman-Michael, and Y. Yarden. 1992. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. J. Biol. Chem. 267:17304-17313.
5. Blechman, J. M., S. Lev, J. Barg, M. Eisenstein, B. Vaks, Z. Vogel, D. Givol, and Y. Yarden. 1995. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80:103-113.
6. neu activation. EMBO J. 11:923-932.
7. Carraway, K. L., and L. C. Cantley. 1994. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8.
8. Carraway, K. L., M. X. Sliwkowski, R. Akita, J. V. Platko, P. M. Guy, A. Nuijens, A. J. Diamonti, R. L. Vandlen, L. C. Cantley, and R. A. Cerione. 1994. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 269:14303-14306.
9. Carraway, K. L., S. P. Soltoff, A. J. Diamonti, and L. C. Cantley. 1995. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270:7111-7116.
10. Chen, X., G. Levkowitz, E. Tzahar, D. Karunagaran, S. Lavi, N. Ben-Baruch, O. Leitner, B. Ratzkin, S. S. Bacus, and Y. Yarden. 1996. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem. 271:7620-7629.
11. Cohen, B., J. M. Green, L. Foy, and P. H. Fell. 1996. HER4-mediated biological and biochemical properties in NIH 3T3 cells. J. Biol. Chem. 271:4813-4818.
12. Dougall, W. C., X. Qian, N. C. Peterson, M. J. Miller, A. Samanta, and M. Greene. 1994. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109-2123.
13. Evan, G. I., G. K. Lewis, G. Ramsay, and J. M. Bishop. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5:3610-3616.
14. Fantl, W. J., D. E. Johnson, and L. T. Williams. 1993. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62:453-481.
15. Goldman, R., R. Ben-Levy, E. Peles, and Y. Yarden. 1990. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29:11024-11028.
16. Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1182-1191.
17. Gullick, W. J. 1994. A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur. J. Cancer 30A:2186.
18. Gullick, W. J., M. S. Berger, P. L. Bennett, J. B. Rothbard, and M. D. Waterfield. 1987. Expression of the c-erbB-2 protein in normal and transformed cells. Int. J. Cancer 40:246-254.
19. Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway. 1994. Insect cell-expressed p180ErbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91:8132-8136.
20. Hammacher, A., K. Mellstrom, C.-H. Heldin, and B. Westermark. 1989. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J. 8:2489-2495.
21. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
22. Karunagaran, D., E. Tzahar, R. K. Beerli, X. Chen, D. Graus-Porta, B. Ratzkin, R. Seger, N. E. Hynes, and Y. Yarden. 1996. ErbB-2 is a common signaling subunit of NDF- and EGF-receptors: implications for breast cancer. EMBO J. 15:254-264.
23. Karunagaran, D., E. Tzahar, N. Liu, D. Wen, and Y. Yarden. 1995. Neu differentiation factor inhibits EGF binding: a model for trans-regulation within the ErbB family of receptor tyrosine kinases. J. Biol. Chem. 270:9982-9990.
24. Kim, H.-H., S. L. Sierke, and J. G. Koland. 1994. Epidermal growth factor-dependent association of phosphatidylinositol 3′-kinase with the erbB-3 gene product. J. Biol. Chem. 269:24747-24755.
25. King, C. R., I. Borrello, F. Bellot, P. Comoglio, and J. Schlessinger. 1988. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SKBR-3. EMBO J. 7:1647-1651.
26. King, C. R., M. H. Kraus, and S. A. Aaronson. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976.
27. Kita, Y. A., J. Braff, Y. Luo, D. Wen, D. Brankow, S. Hu, S. A. Prigent, W. J. Gullick, and M. Nicolson. 1994. NDF/heregulin stimulates the phosphorylation of HER3/erbB3. FEBS Lett. 349:139-143.
28. Koch, A. C., D. Anderson, M. F. Moran, C. Ellis, and T. Pawson. 1991. SH-2 and SH-3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252:668-674.
29. Kokai, Y., J. N. Myers, T. Wada, V. I. Brown, C. M. LeVea, J. G. Davis, K. Dobashi, and M. I. Greene. 1989. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292.
30. Lee, J., T. J. Dull, I. Lax, J. Schlessinger, and A. Ullrich. 1989. HER-2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J. 8:167-173.
31. Lehvaslaiho, H., L. Lehtola, L. Sistonen, and K. Alitalo. 1989. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J. 8:159-166.
32. Lonardo, F., E. Di Marco, C. R. King, J. H. Pierce, O. Segatto, S. A. Aaronson, and P. P. Di Fiore. 1990. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2:992-1003.
33. Marikovsky, M., S. Lavi, R. Pinkas-Kramarski, D. Karunagaran, N. Liu, D. Wen, and Y. Yarden. 1995. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10:1403-1411.
34. Massagué, J. 1990. Transforming growth factor-α: a model for membrane anchored growth factors. J. Biol. Chem. 265:21393-21396.
35. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniqes 7:980-990.
36. Munson, P. J., and D. Rodbard. 1980. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:220-239.
37. Park, J. G., H. Frucht, R. V. LaRocca, D. P. J. Bliss, Y. Kurita, T.-R. Chen, J. G. Henslee, J. B. Trepel, R. T. Jensen, B. E. Johnson, Y. J. Bang, J.-P. Kim, and A. F. Gazdar. 1990. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 50:2773-2780.
38. Pawson, T., and J. Schlessinger. 1993. SH2 and SH3 domains. Curr. Biol. 3:434-442.
39. Peles, E., R. Ben-Levy, E. Or, A. Ullrich, and Y. Yarden. 1991. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ. EMBO J. 10:2077-2086.
40. Peles, E., R. Ben-Levy, E. Tzahar, L. Naili, D. Wen, and Y. Yarden. 1993. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2. EMBO J. 12:961-971.
41. Peles, E., and Y. Yarden. 1993. Neu and its ligands: from an oncogene to neural factors. Bioessays 15:815-824.
42. Plowman, G. D., J. M. Green, J.-M. Culouscou, G. W. Carlton, V. M. Rothwell, and B. Sharon. 1993. Heregulin induces tyrosine phosphorylation of HER4/p180erbB-4. Nature (London) 366:473-475.
43. Prigent, S. A., and N. R. Lemoine. 1992. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Proc. Growth Factor Res. 4:1-24.
44. Riese, D. J., T. M. van Raaij, G. D. Plowman, G. C. Andrews, and D. F. Stern. 1995. The cellular response to neuregulins is governed by complex interactions of the ErbB receptor family. Mol. Cell. Biol. 15:5770-5776.
45. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
46. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
47. Sliwkowski, M. X., G. Schaefer, R. W. Akita, J. A. Lofgren, V. D. Fitzpatrick, A. Nuijens, B. M. Fendly, R. A. Cerione, R. L. Vandlen, and K. L. Carraway. 1994. Coexpression of erbB2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:14661-14665.
48. Soltoff, S. P., K. L. Carraway, S. A. Prigent, W. G. Gullick, and L. C. Cantley. 1994. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14:3550-3558.
49. Soos, M. A., J. Whittaker, R. Lammers, A. Ullrich, and K. Siddle. 1990. Receptors for insulin and insulin-like growth factor 1 form hybrid dimers. Biochem. J. 270:383-390.
50. Stancovski, I., E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden, and M. Sela. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88:8691-8695.
51. Stancovski, I., M. Sela, and Y. Yarden. 1994. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase, p. 161-191. In M. Lippman and R. Dikson (ed.), Regulatory mechanisms of breast cancer. Kluwer Academic Publishers, Boston.
52. neu: a potential model for receptor interactions. EMBO J. 7:995-1001.
53. Sternberg, M. J., and W. J. Gullick. 1990. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng. 3:245-248.
54. Tzahar, E., G. Levkowitz, D. Karunagaran, L. Yi, E. Peles, S. Lavi, D. Chang, N. Liu, A. Yayon, D. Wen, and Y. Yarden. 1994. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all NDF/heregulin isoforms. J. Biol. Chem. 269:25226-25233.
55. van der Geer, P., T. Hunter, and R. A. Lindberg. 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10:251-337.
56. neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339-1347.
57. Wallasch, C., F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich. 1995. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14:4267-4275.
58. Weiner, D. B., J. Liu, J. A. Cohen, W. V. Williams, and M. I. Greene. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (London) 339:230-231.
59. Wen, D., S. V. Suggs, D. Karunagaran, N. Liu, R. L. Cupples, Y. Luo, A. M. Jansen, N. Ben-Baruch, D. B. Trollinger, V. L. Jacobson, T. Meng, H. S. Lu, S. Hu, D. Chang, D. Yanigahara, R. A. Koski, and Y. Yarden. 1994. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol. 14:1909-1919.
60. Yarden, Y. 1990. Agonistic antibodies stimulate the kinase encoded by the neu proto-oncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA 87:2569-2573.
61. Yarden, Y., and J. Schlessinger. 1987. Epidermal growth factor induce rapid, reversible aggregation of purified epidermal growth factor receptor. Biochemistry 26:1443-1445.
62. Yarden, Y., and A. Ulrich. 1988. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57:443-478.